Michael C. Kaufman

Michael C. Kaufman

Auto-generated profile, based on publicly available information

Michael C. Kaufman

Division of Neurology, Children's Hospital of Philadelphia, PA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2021 in Brain
Verified
Journal Article
Open access
PDF file
JXJulie Xian
Julie Xian
SPShridhar Parthasarathy
Shridhar Parthasarathy
SRSarah M Ruggiero
Sarah M Ruggiero
GBGanna Balagura
Ganna Balagura
EFEryn Fitch
Eryn Fitch
IHIngo Helbig
Ingo Helbig
Disease-causing variants in STXBP1 are among the most common genetic causes of neurodevelopmental disorders. However, the phenotypic spectrum in STXBP1-related disorders is wide and clear correlations between variant type and clinical features have not been observed so far. Here, we harmonized clinical data across 534 individuals with STXBP1-related disorders and analysed 19 973 derived phenotypic terms, including phenotypes of 253 individuals previously unreported in the scientific literature. The overall phenotypic landscape in STXBP1-related disorders is characterized by neurodevelopmental abnormalities in 95% and seizures in 89% of individuals, including focal-onset seizures as the most common seizure type (47%). More than 88% of individuals with STXBP1-related disorders have seizure onset in the first year of life, including neonatal seizure onset in 47%. Individuals with protein-truncating variants and deletions in STXBP1 (n = 261) were almost twice as likely to present with West syndrome and were more phenotypically similar than expected by chance. Five genetic hotspots with recurrent variants were identified in more than 10 individuals, including p.Arg406Cys/His (n = 40), p.Arg292Cys/His/Leu/Pro (n = 30), p.Arg551Cys/Gly/His/Leu (n = 24), p.Pro139Leu (n = 12), and p.Arg190Trp (n = 11). None of the recurrent variants were significantly associated with distinct electroclinical syndromes, single phenotypic features, or showed overall clinical similarity, indicating that the baseline variability in STXBP1-related disorders is too high for discrete phenotypic subgroups to emerge. We then reconstructed the seizure history in 62 individuals with STXBP1-related disorders in detail, retrospectively assigning seizure type and seizure frequency monthly across 4433 time intervals, and retrieved 251 anti-seizure medication prescriptions from the electronic medical records. We demonstrate a dynamic pattern of seizure control and complex interplay with response to specific medications particularly in the first year of life when seizures in STXBP1-related disorders are the most prominent. Adrenocorticotropic hormone and phenobarbital were more likely to initially reduce seizure frequency in infantile spasms and focal seizures compared to other treatment options, while the ketogenic diet was most effective in maintaining seizure freedom. In summary, we demonstrate how the multidimensional spectrum of phenotypic features in STXBP1-related disorders can be assessed using a computational phenotype framework to facilitate the development of future precision-medicine approaches.

1 September 2020 in Neurology
Verified
Journal Article
Open access
PDF file
SRSalvatore C. Rametta
Salvatore C. Rametta
SFSara E. Fridinger
Sara E. Fridinger
AGAlexander K. Gonzalez
Alexander K. Gonzalez
JXJulie Xian
Julie Xian
PGPeter D. Galer
Peter D. Galer
IHIngo Helbig
Ingo Helbig
Objective To assess the rapid implementation of child neurology telehealth outpatient care with the onset of the coronavirus disease 2019 (COVID-19) pandemic in March 2020. Methods This was a cohort study with retrospective comparison of 14,780 in-person encounters and 2,589 telehealth encounters, including 2,093 audio-video telemedicine and 496 scheduled telephone encounters, between October 1, 2019 and April 24, 2020. We compared in-person and telehealth encounters for patient demographics and diagnoses. For audio-video telemedicine encounters, we analyzed questionnaire responses addressing provider experience, follow-up plans, technical quality, need for in-person assessment, and parent/caregiver satisfaction. We performed manual reviews of encounters flagged as concerning by providers. Results There were no differences in patient age and major ICD-10 codes before and after transition. Clinicians considered telemedicine satisfactory in 93% (1,200 of 1,286) of encounters and suggested telemedicine as a component for follow-up care in 89% (1,144 of 1,286) of encounters. Technical challenges were reported in 40% (519 of 1,314) of encounters. In-person assessment was considered warranted after 5% (65 of 1,285) of encounters. Patients/caregivers indicated interest in telemedicine for future care in 86% (187 of 217) of encounters. Participation in telemedicine encounters compared to telephone encounters was less frequent among patients in racial or ethnic minority groups. Conclusions We effectively converted most of our outpatient care to telehealth encounters, including mostly audio-video telemedicine encounters. Providers rated the vast majority of telemedicine encounters to be satisfactory, and only a small proportion of encounters required short-term in-person follow-up. These findings suggest that telemedicine is feasible and effective for a large proportion of child neurology care. Additional strategies are needed to ensure equitable telemedicine use.

20 September 2022 in Neurology
Verified
Journal Article
Closed access
PDF file
MJMarin Jacobwitz
Marin Jacobwitz
CMCaitlyn Mulvihill
Caitlyn Mulvihill
MKMichael C. Kaufman
Michael C. Kaufman
AGAlexander K. Gonzalez
Alexander K. Gonzalez
KRKarla Resendiz
Karla Resendiz
NANicholas S. Abend
Nicholas S. Abend
Objective: Few data are available regarding the use of anesthetic infusions for refractory status epilepticus (RSE) in children and neonates, and ketamine use is increasing despite limited data. We aimed to describe the impact of ketamine for RSE in children and neonates. Methods: Retrospective single-center cohort study of consecutive patients admitted to the intensive care units of a quaternary care children’s hospital treated with ketamine infusion for RSE. Results: Sixty-nine patients were treated with a ketamine infusion for RSE. The median age at onset of RSE was 0.7 years (IQR 0.15-7.2), and the cohort included 13 (19%) neonates. Three patients (4%) had adverse events requiring intervention during or within twelve hours of ketamine administration, including hypertension in 2 patients and delirium in 1 patient. Ketamine infusion was followed by seizure termination in 32 (46%) patients, seizure reduction in 19 (28%) patients, and no change in 18 (26%) patients. Discussion: Ketamine administration was associated with few adverse events, and seizures often terminated or improved after ketamine administration. Further data are needed comparing first-line and subsequent anesthetic medications for treatment of pediatric and neonatal RSE. Classification of Evidence: This study provides Class IV evidence on the therapeutic utility of ketamine for treatment of RSE in children and neonates.

28 February 2022 in Developmental Medicine & Child Neurology
Verified
Journal Article
Closed access
SCStacey R. Cohen
Stacey R. Cohen
IHIngo Helbig
Ingo Helbig
MKMichael C. Kaufman
Michael C. Kaufman
LMLeah Schust Myers
Leah Schust Myers
LCLaura Conway
Laura Conway
KHKatherine L. Helbig
Katherine L. Helbig

2 June 2021 in Epilepsia
Verified
Journal Article
Closed access
PDF file
MFMark P. Fitzgerald
Mark P. Fitzgerald
MKMichael C. Kaufman
Michael C. Kaufman
SMShavonne L. Massey
Shavonne L. Massey
SFSara Fridinger
Sara Fridinger
MPMarisa Prelack
Marisa Prelack
IHIngo Helbig
Ingo Helbig

21 October 2025 in Neurology
Verified
Journal Article
Closed access
PGPeter D. Galer
Peter D. Galer
JMJillian L. McKee
Jillian L. McKee
SRSarah M. Ruggiero
Sarah M. Ruggiero
MKMichael C. Kaufman
Michael C. Kaufman
WOWilliam K.S. Ojemann
William K.S. Ojemann
ECErin C. Conrad
Erin C. Conrad
EEG plays an integral part in the diagnosis and management of children with genetic epilepsies. Nevertheless, how quantitative EEG features differ between genetic epilepsies and neurologic outcomes remains largely unknown. In this study, we aimed to identify quantitative EEG biomarkers in STXBP1-related, SCN1A-related, and SYNGAP1-related childhood epilepsy and associated neurologic outcomes. We retrospectively collected clinical scalp EEGs from the Children's Hospital of Philadelphia. After removing artifacts and epochs with excess noise or altered state from EEGs, we extracted spectral features. We validated our preprocessing pipeline by comparing automatically detected posterior dominant rhythm (PDR) with annotations from clinical EEG reports. Next, as a coarse measure of pathologic slowing, we compared the alpha-delta bandpower ratio between controls and patients with different genetic epilepsies. We then trained random forest models with localized spectral features to predict diagnoses of STXBP1, SCN1A, and SYNGAP1 and estimate seizure frequency and motor function across a broader cohort. We evaluated EEGs from individuals with pathogenic variants in STXBP1 (95 EEGs, n = 20; 40% female; mean age 3.98 years), SCN1A (154 EEGs, n = 68; 51% female; mean age 6.24 years), and SYNGAP1 (46 EEGs, n = 21; 57% female; mean age 6.97 years) and neurotypical controls (847 EEGs, n = 806; 55% female; mean age 7.08 years). There was strong agreement between the automatically calculated PDR and annotations from clinical EEG reports (R2 = 0.75). Individuals with STXBP1-related epilepsy had a significantly lower alpha-delta ratio than controls (median Cohen d = -0.95, p < 0.001) across all ages. Models accurately predicted a diagnosis of STXBP1 (area under the curve [AUC] = 0.92), SYNGAP1 (AUC = 0.86), and SCN1A (AUC = 0.85) against controls and each other (accuracy = 0.74). From these models, we isolated highly correlated biomarkers, including the alpha-theta ratio in frontal, occipital, and parietal electrodes associated with STXBP1, SYNGAP1, and SCN1A, respectively. Models were unable to predict seizure frequency (AUC = 0.53). Models predicted motor scores significantly better than age-based null models (p < 0.001). These results suggest that some genetic epilepsies and functional outcome measures have distinct quantitative EEG signatures. Furthermore, EEG spectral features are predictive of some functional outcome measures. Large-scale retrospective quantitative analysis of clinical EEGs has the potential to discover novel biomarkers and to quantify and track individuals' disease progression across development.